Benaroya Research Institute at Virginia Mason, Seattle, WA 98101-2795, USA.
Curr Opin Immunol. 2012 Dec;24(6):700-6. doi: 10.1016/j.coi.2012.07.009. Epub 2012 Aug 10.
Allergen specific T(H)2 cells are a key component of allergic disease, but their characterization has been hindered by technical limitations and lack of epitope data. Knowledge about the factors that drive the differentiation of naïve T cells into allergy-promoting T(H)2 cells and the influence of allergen specific immunotherapy on the phenotype and function of allergen-specific T cells have also been limited. Recent advances indicate that innate and adaptive immune factors drive the development of diverse subsets of allergen-specific T cells. While allergen-specific T cells are present even in non-allergic subjects, highly differentiated T(H)2 cells are present only in allergic subjects and their disappearance correlates with successful immunotherapy. Therefore, elimination of pathogenic T(H)2 cells is an essential step in tolerance induction.
过敏原特异性 T(H)2 细胞是过敏疾病的关键组成部分，但由于技术限制和缺乏表位数据，其特征一直难以确定。对于驱动初始 T 细胞分化为促进过敏的 T(H)2 细胞的因素以及过敏原特异性免疫疗法对过敏原特异性 T 细胞表型和功能的影响，我们的了解也有限。最近的进展表明，先天和适应性免疫因素驱动了过敏原特异性 T 细胞的多种亚群的发展。虽然过敏原特异性 T 细胞甚至存在于非过敏个体中，但高度分化的 T(H)2 细胞仅存在于过敏个体中，它们的消失与免疫治疗的成功相关。因此，消除致病性 T(H)2 细胞是诱导耐受的必要步骤。
